Clinicopathological characteristics of KRAS and BRAF mutation in 138 patients with rectosigmoid cancer
1.Wenzhou Medical University, Wenzhou, 325035; 2.Department of Surgical Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015
YANG Fan1,CAI Yefeng1,JIN Langping1, et al. Clinicopathological characteristics of KRAS and BRAF mutation in 138 patients with rectosigmoid cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(9): 646-.
Abstract：Objective: To identify the mutation rate and mutation feature of KRAS and BRAF gene in patients with rectosigmoid carcinoma, to analyse the association between KRAS/BRAF mutations and patients’ clinicopathological characteristics, and discuss the clinical significance of KRAS/BRAF mutations. Methods: 138 patients with rectosigmoid carcinoma were collected. DNA sequencing was used to detect mutations in KRAS (codons12, 13 of exon2 and codons 61 of exon3) and BRAF (exon15). Statistically analyzing the relationships between gene mutations and clinicopathological characteristic. Results: In 138 cases, the mutation rate of KRAS and BRAF was 34.05% (47/138) and 5.07% (7/138). 9 mutation types were found in KRAS, including a new mutation type. BRAF mutation was all belong to V600E mutation. In patients with rectosigmoid carcinoma, KRAS mutation rate was higher in male (P=0.041), distant metastasis (P=0.002) and high clinical stages (P=0.047). BRAF mutation rate was higher in multiple (P=0.003) and poorly differentiate (P=0.001) carcinoma. No significant associations were observed between KRAS/BRAF mutations and age, tumor size, pathomorphism, pathological type, depth of invasion, lymph node metastasis, vessel infiltration and nervous infiltration (P>0.05). Conclusion: Rectosigmoid carcinoma is unique. KRAS mutation rate is higher in male, distant metastasis and high clinical stages carcinoma. BRAF mutation rate is higher in multiple and poorly differentiate carcinoma.KRAS and BRAF mutations are variant in different location of colorectal cancer.
